NEW YORK -- Stocks ended the day little changed Wednesday after a rally prompted by the Federal Reserve's latest economic stimulus program fizzled out.
The Dow Jones industrial average closed down 2.99 points at 13,245.45. It had risen as much as 81 points after the Fed said earlier in the day that it would extend a bond-buying plan and keep interest extremely low.
The S&P finished 0.64 points higher at 1,428.48. The Nasdaq composite was down 8.49 points at 3,013.81.
The Fed said it will keep spending $85 billion a month on bond purchases to drive down long-term borrowing costs and stimulate economic growth. Of that amount it will spend $45 billion on long-term Treasury purchases to replace a previous bond-buying program of equal size.
The central bank also said it would keep its key short-term interest rate near zero at least until the unemployment rate drops below 6.5 percent or inflation rises to 2.5 percent. Previously, it had said that it expects to keep the rate low until at least mid-2015.
The enthusiasm over the Fed's announcement, which came at 12:30 p.m., was short-lived. It briefly drew investors' attention away from the tense, high-level budget talks taking place in Washington.
Also, the amount of bond buying the central bank said it would undertake was in line with what investors were expecting, Joseph Tanious, a Global Market Strategist with J.P. Morgan Funds, said. "I don't think you're seeing markets react hugely" to the Fed, he said. "Clearly what is driving markets right now is the fiscal policy. What's holding markets hostage ... is uncertainty around the fiscal cliff."
In Washington, lawmakers were still trying to reach a deal to avoid the fiscal "cliff," a series of sharp tax increases and spending cuts that will hit the economy in January if Congress and President Barack Obama are unable to thrash out an agreement to reduce the U.S. budget deficit.
Chemicals giant DuPont advanced 61 cents, or 1.4 percent, to $44.30 after the company unveiled plans to buy back up to $1 billion of its shares next year and said that profit for this year will reach the high end of its forecasts.
Eli Lilly and Co. fell $1.60 to $49 after the Indianapolis drugmaker said it will conduct the additional, late-stage study of its possible Alzheimer's treatment solanezumab. The move delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the disease.
Health insurer Aetna Inc. rose $1.43 to $45.91 after the company said late Tuesday that it expects sales and profit to grow next year.businessnews